<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04075409</url>
  </required_header>
  <id_info>
    <org_study_id>UP0083</org_study_id>
    <secondary_id>JapicCTI-194958</secondary_id>
    <nct_id>NCT04075409</nct_id>
  </id_info>
  <brief_title>A Study to Test the Safety, and Tolerability of Padsevonil in Healthy Male Japanese Study Participants</brief_title>
  <official_title>An Open-Label, Parallel Group, Single-Center Study to Investigate the Pharmacokinetic, Safety, and Tolerability Profiles of Padsevonil in CYP2C19 Genotyped Healthy Male Japanese Study Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the pharmacokinetics (PK) of padesevonil in&#xD;
      CYP2C19 genotyped healthy male Japanese study participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Actual">December 27, 2019</completion_date>
  <primary_completion_date type="Actual">December 27, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of a Single Dose Padsevonil</measure>
    <time_frame>Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose (up to Day 3)</time_frame>
    <description>Cmax is the maximum plasma drug concentration of PSL observed from pharmacokinetic samples taken at predefined time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From 0 to t (AUC(0-t)) of a Single Dose Padsevonil</measure>
    <time_frame>Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose (up to Day 3)</time_frame>
    <description>AUC(0-t) is the area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time 0 to Infinity (AUC) of a Single Dose Padsevonil</measure>
    <time_frame>Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose (up to Day 3)</time_frame>
    <description>AUC is the area under the plasma concentration-time curve from time zero to infinity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-life (t1/2) of a Single Dose Padsevonil</measure>
    <time_frame>Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose (up to Day 3)</time_frame>
    <description>The t1/2 is the apparent terminal half-life. Geometric Means and Geometric Coefficient of Variations were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach the Maximum Plasma Concentration (Tmax) of a Single Dose Padsevonil</measure>
    <time_frame>Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose (up to Day 3)</time_frame>
    <description>The tmax is the time to reach maximum plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Padsevonil at Steady-state (ss)</measure>
    <time_frame>Day 10: Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after the morning dose</time_frame>
    <description>Cmax, ss is the maximum plasma concentration of PSL observed from pharmacokinetic samples, taken at predefined time point at a steady-state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve Over a Dosing Interval (AUCtau) of Multiple Doses Padsevonil</measure>
    <time_frame>Day 10: Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after the morning dose</time_frame>
    <description>AUCtau is the area under the plasma concentration time curve over a dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-life (t1/2) of Multiple Doses Padsevonil</measure>
    <time_frame>Day 10: Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after the morning dose</time_frame>
    <description>The t1/2 is the apparent terminal half-life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Concentration (Tmax) for Padsevonil at Steady-state (ss)</measure>
    <time_frame>Day 10: Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after the morning dose</time_frame>
    <description>The tmax, ss is the time of observed maximum plasma concentration at a steady-state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment Emergent Adverse Events During the Study</measure>
    <time_frame>From Baseline until the Safety Follow-up Visit (up to Day 21)</time_frame>
    <description>An Adverse Event (AE) is any untoward medical occurrence in a participant or trial participant that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Healthy Japanese Participants</condition>
  <arm_group>
    <arm_group_label>Extensive metabolizers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive assigned single and multiple doses of padsevonil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate metabolizers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive assigned single and multiple doses of padsevonil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Poor metabolizers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive assigned single and multiple doses of padsevonil.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Padsevonil</intervention_name>
    <description>Padsevonil will be administered in predefined dosages.</description>
    <arm_group_label>Extensive metabolizers</arm_group_label>
    <arm_group_label>Intermediate metabolizers</arm_group_label>
    <arm_group_label>Poor metabolizers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The study participant must be 20 to 55 years of age inclusive, at the time of signing&#xD;
             the informed consent&#xD;
&#xD;
          -  The study participant is overtly healthy as determined by medical evaluation including&#xD;
             medical history, physical examination, laboratory tests, and cardiac monitoring&#xD;
&#xD;
          -  The study participant is of Japanese descent as evidenced by appearance and verbal&#xD;
             confirmation of familial heritage&#xD;
&#xD;
          -  The study participant has a body weight â‰¥50 kg and body mass index within the range&#xD;
             [18 to 30] kg/m^2 (inclusive)&#xD;
&#xD;
          -  The study participant is male&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The study participant has any medical or psychiatric condition that, in the opinion of&#xD;
             the Investigator, could jeopardize or would compromise the study participant's ability&#xD;
             to participate in this study, such as a history of schizophrenia, or other psychotic&#xD;
             disorder, bipolar disorder, or severe unipolar depression. The presence of potential&#xD;
             psychiatric exclusion criteria will be determined based on the psychiatric history&#xD;
             collected at the Screening Visit&#xD;
&#xD;
          -  The study participant has a history or presence of cardiovascular, respiratory,&#xD;
             hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological&#xD;
             disorders, capable of significantly altering the absorption, metabolism, or&#xD;
             elimination of drugs; constituting a risk when taking the study intervention; or&#xD;
             interfering with the interpretation of data&#xD;
&#xD;
          -  The study participant has a history of unexplained syncope or a family history of&#xD;
             sudden death due to long QT syndrome&#xD;
&#xD;
          -  The study participant has a lifetime history of suicide attempt (including an actual&#xD;
             attempt, interrupted attempt, or aborted attempt), or has had suicidal ideation in the&#xD;
             past 6 months as indicated by a positive response (&quot;Yes&quot;) to either Question 4 or&#xD;
             Question 5 of the &quot;Screening/Baseline&quot; version of the Columbia-Suicide Severity Rating&#xD;
             Scale (C-SSRS) at Screening&#xD;
&#xD;
          -  The study participant has alanine aminotransferase (ALT), aspartate aminotransferase&#xD;
             (AST), or alkaline phosphatase (ALP) &gt;1.0 x upper limit of normal (ULN)&#xD;
&#xD;
          -  The study participant has bilirubin &gt;1.0 x ULN (isolated bilirubin &gt;1.0 x ULN is&#xD;
             acceptable if bilirubin is fractionated and direct bilirubin &lt;35 %)&#xD;
&#xD;
          -  The study participant has current or chronic history of liver disease or known hepatic&#xD;
             or biliary abnormalities&#xD;
&#xD;
          -  The study participant has any clinically relevant electrocardiogram (ECG) finding at&#xD;
             the Screening Visit or at Baseline.&#xD;
&#xD;
          -  The study participant has made a blood or plasma donation or has had a comparable&#xD;
             blood loss (&gt;450 mL) within the last 30 days prior to Screening. Blood donation during&#xD;
             the study is not permitted&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>001 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Up0083 001</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>August 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <results_first_submitted>April 30, 2021</results_first_submitted>
  <results_first_submitted_qc>June 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 8, 2021</results_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Padsevonil</keyword>
  <keyword>CYP2C19</keyword>
  <keyword>Healthy Japanese Participants</keyword>
  <keyword>Pharmacokinetics</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Due to the small sample size in this trial, Individual Patient Data cannot be adequately anonymized and there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT04075409/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 10, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT04075409/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study started to enroll patients in September 2019 and concluded in December 2019.</recruitment_details>
      <pre_assignment_details>Participant flow refers to the Safety Set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Extensive Metabolizers</title>
          <description>Extensive metabolizers (Participants confirmed with genotype *1/*1) received a single oral dose of padsevonil (PSL) 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg twice a day (BID) on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally.</description>
        </group>
        <group group_id="P2">
          <title>Intermediate Metabolizers</title>
          <description>Intermediate metabolizers (Participants confirmed with genotype *1/*2,*1/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally.</description>
        </group>
        <group group_id="P3">
          <title>Poor Metabolizers</title>
          <description>Poor metabolizers (Participants confirmed with genotype *2/*2, *2/*3, *3/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Characteristics refer to the Safety Set (SS) which consisted of all enrolled participants who received at least 1 dose of Padsevonil (PSL).</population>
      <group_list>
        <group group_id="B1">
          <title>Extensive Metabolizers</title>
          <description>Extensive metabolizers (Participants confirmed with genotype *1/*1) received a single oral dose of padsevonil (PSL) 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg twice a day (BID) on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally.</description>
        </group>
        <group group_id="B2">
          <title>Intermediate Metabolizers</title>
          <description>Intermediate metabolizers (Participants confirmed with genotype *1/*2,*1/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally.</description>
        </group>
        <group group_id="B3">
          <title>Poor Metabolizers</title>
          <description>Poor metabolizers (Participants confirmed with genotype *2/*2, *2/*3, *3/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally.</description>
        </group>
        <group group_id="B4">
          <title>Total Title</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.5" spread="6.6"/>
                    <measurement group_id="B2" value="32.5" spread="5.9"/>
                    <measurement group_id="B3" value="32.5" spread="7.7"/>
                    <measurement group_id="B4" value="30.9" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of a Single Dose Padsevonil</title>
        <description>Cmax is the maximum plasma drug concentration of PSL observed from pharmacokinetic samples taken at predefined time points.</description>
        <time_frame>Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose (up to Day 3)</time_frame>
        <population>The Pharmacokinetic Per-protocol Set (PK-PPS) was a subset of the Safety Set, consisting of those study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Poor Metabolizers (PK-PPS)</title>
            <description>Poor metabolizers (Participants confirmed with genotype *2/*2, *2/*3, *3/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Metabolizers (PK-PPS)</title>
            <description>Intermediate metabolizers (Participants confirmed with genotype *1/*2,*1/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O3">
            <title>Extensive Metabolizers (PK-PPS)</title>
            <description>Extensive metabolizers (Participants confirmed with genotype *1/*1) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of a Single Dose Padsevonil</title>
          <description>Cmax is the maximum plasma drug concentration of PSL observed from pharmacokinetic samples taken at predefined time points.</description>
          <population>The Pharmacokinetic Per-protocol Set (PK-PPS) was a subset of the Safety Set, consisting of those study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1029" lower_limit="832.5" upper_limit="1272"/>
                    <measurement group_id="O2" value="833.6" lower_limit="674.6" upper_limit="1030"/>
                    <measurement group_id="O3" value="721.3" lower_limit="583.6" upper_limit="891.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Point estimates for the geometric least squares (LS) means ratio and the respective 2-sided 90% Confidence Intervals (CIs) were computed using the LS means and the root mean squares of error, based on of the log-transformed data with subsequent exponential transformation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS means ratio</param_type>
            <param_value>1.426</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.112</ci_lower_limit>
            <ci_upper_limit>1.830</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Point estimates for the geometric least squares (LS) means ratio and the respective 2-sided 90% CIs were computed using the LS means and the root mean squares of error, based on of the log-transformed data with subsequent exponential transformation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS means ratio</param_type>
            <param_value>1.234</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9619</ci_lower_limit>
            <ci_upper_limit>1.584</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Point estimates for the geometric least squares (LS) means ratio and the respective 2-sided 90% CIs were computed using the LS means and the root mean squares of error, based on of the log-transformed data with subsequent exponential transformation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS means ratio</param_type>
            <param_value>1.156</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9008</ci_lower_limit>
            <ci_upper_limit>1.483</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From 0 to t (AUC(0-t)) of a Single Dose Padsevonil</title>
        <description>AUC(0-t) is the area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration.</description>
        <time_frame>Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose (up to Day 3)</time_frame>
        <population>The Pharmacokinetic Per-protocol Set (PK-PPS) was a subset of the Safety Set, consisting of those study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter</population>
        <group_list>
          <group group_id="O1">
            <title>Poor Metabolizers (PK-PPS)</title>
            <description>Poor metabolizers (Participants confirmed with genotype *2/*2, *2/*3, *3/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Metabolizers (PK-PPS)</title>
            <description>Intermediate metabolizers (Participants confirmed with genotype *1/*2,*1/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O3">
            <title>Extensive Metabolizers (PK-PPS)</title>
            <description>Extensive metabolizers (Participants confirmed with genotype *1/*1) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From 0 to t (AUC(0-t)) of a Single Dose Padsevonil</title>
          <description>AUC(0-t) is the area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration.</description>
          <population>The Pharmacokinetic Per-protocol Set (PK-PPS) was a subset of the Safety Set, consisting of those study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter</population>
          <units>h*ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5988" lower_limit="4976" upper_limit="7206"/>
                    <measurement group_id="O2" value="4645" lower_limit="3860" upper_limit="5589"/>
                    <measurement group_id="O3" value="2823" lower_limit="2346" upper_limit="3397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Point estimates for the geometric least squares (LS) means ratio and the respective 2-sided 90% CIs were computed using the LS means and the root mean squares of error, based on of the log-transformed data with subsequent exponential transformation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS means ratio</param_type>
            <param_value>2.122</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.706</ci_lower_limit>
            <ci_upper_limit>2.638</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Point estimates for the geometric least squares (LS) means ratio and the respective 2-sided 90% CIs were computed using the LS means and the root mean squares of error, based on of the log-transformed data with subsequent exponential transformation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS means ratio</param_type>
            <param_value>1.289</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.037</ci_lower_limit>
            <ci_upper_limit>1.603</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Point estimates for the geometric least squares (LS) means ratio and the respective 2-sided 90% CIs were computed using the LS means and the root mean squares of error, based on of the log-transformed data with subsequent exponential transformation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS means ratio</param_type>
            <param_value>1.646</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.323</ci_lower_limit>
            <ci_upper_limit>2.046</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time 0 to Infinity (AUC) of a Single Dose Padsevonil</title>
        <description>AUC is the area under the plasma concentration-time curve from time zero to infinity.</description>
        <time_frame>Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose (up to Day 3)</time_frame>
        <population>The Pharmacokinetic Per-protocol Set (PK-PPS) was a subset of the Safety Set, consisting of those study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter</population>
        <group_list>
          <group group_id="O1">
            <title>Poor Metabolizers (PK-PPS)</title>
            <description>Poor metabolizers (Participants confirmed with genotype *2/*2, *2/*3, *3/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Metabolizers (PK-PPS)</title>
            <description>Intermediate metabolizers (Participants confirmed with genotype *1/*2,*1/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O3">
            <title>Extensive Metabolizers (PK-PPS)</title>
            <description>Extensive metabolizers (Participants confirmed with genotype *1/*1) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time 0 to Infinity (AUC) of a Single Dose Padsevonil</title>
          <description>AUC is the area under the plasma concentration-time curve from time zero to infinity.</description>
          <population>The Pharmacokinetic Per-protocol Set (PK-PPS) was a subset of the Safety Set, consisting of those study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter</population>
          <units>h*ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6024" lower_limit="5009" upper_limit="7245"/>
                    <measurement group_id="O2" value="4666" lower_limit="3879" upper_limit="5611"/>
                    <measurement group_id="O3" value="2837" lower_limit="2359" upper_limit="3412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Point estimates for the geometric least squares (LS) means ratio and the respective 2-sided 90% CIs were computed using the LS means and the root mean squares of error, based on of the log-transformed data with subsequent exponential transformation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS means ratio</param_type>
            <param_value>2.124</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.709</ci_lower_limit>
            <ci_upper_limit>2.639</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Point estimates for the geometric least squares (LS) means ratio and the respective 2-sided 90% CIs were computed using the LS means and the root mean squares of error, based on of the log-transformed data with subsequent exponential transformation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS means ratio</param_type>
            <param_value>1.291</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.039</ci_lower_limit>
            <ci_upper_limit>1.604</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Point estimates for the geometric least squares (LS) means ratio and the respective 2-sided 90% CIs were computed using the LS means and the root mean squares of error, based on of the log-transformed data with subsequent exponential transformation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS means ratio</param_type>
            <param_value>1.645</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.324</ci_lower_limit>
            <ci_upper_limit>2.044</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Half-life (t1/2) of a Single Dose Padsevonil</title>
        <description>The t1/2 is the apparent terminal half-life. Geometric Means and Geometric Coefficient of Variations were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged).</description>
        <time_frame>Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose (up to Day 3)</time_frame>
        <population>The Pharmacokinetic Per-protocol Set (PK-PPS) was a subset of the Safety Set, consisting of those study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Extensive Metabolizers (PK-PPS)</title>
            <description>Extensive metabolizers (Participants confirmed with genotype *1/*1) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Metabolizers (PK-PPS)</title>
            <description>Intermediate metabolizers (Participants confirmed with genotype *1/*2,*1/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O3">
            <title>Poor Metabolizers (PK-PPS)</title>
            <description>Poor metabolizers (Participants confirmed with genotype *2/*2, *2/*3, *3/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (t1/2) of a Single Dose Padsevonil</title>
          <description>The t1/2 is the apparent terminal half-life. Geometric Means and Geometric Coefficient of Variations were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged).</description>
          <population>The Pharmacokinetic Per-protocol Set (PK-PPS) was a subset of the Safety Set, consisting of those study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.018" spread="22.2"/>
                    <measurement group_id="O2" value="5.904" spread="21.3"/>
                    <measurement group_id="O3" value="6.138" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach the Maximum Plasma Concentration (Tmax) of a Single Dose Padsevonil</title>
        <description>The tmax is the time to reach maximum plasma concentration.</description>
        <time_frame>Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose (up to Day 3)</time_frame>
        <population>The Pharmacokinetic Per-protocol Set (PK-PPS) was a subset of the Safety Set, consisting of those study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Extensive Metabolizers (PK-PPS)</title>
            <description>Extensive metabolizers (Participants confirmed with genotype *1/*1) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Metabolizers (PK-PPS)</title>
            <description>Intermediate metabolizers (Participants confirmed with genotype *1/*2,*1/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O3">
            <title>Poor Metabolizers (PK-PPS)</title>
            <description>Poor metabolizers (Participants confirmed with genotype *2/*2, *2/*3, *3/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach the Maximum Plasma Concentration (Tmax) of a Single Dose Padsevonil</title>
          <description>The tmax is the time to reach maximum plasma concentration.</description>
          <population>The Pharmacokinetic Per-protocol Set (PK-PPS) was a subset of the Safety Set, consisting of those study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.000" lower_limit="0.500" upper_limit="4.00"/>
                    <measurement group_id="O2" value="3.000" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="3.000" lower_limit="0.500" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of Padsevonil at Steady-state (ss)</title>
        <description>Cmax, ss is the maximum plasma concentration of PSL observed from pharmacokinetic samples, taken at predefined time point at a steady-state.</description>
        <time_frame>Day 10: Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after the morning dose</time_frame>
        <population>The Pharmacokinetic Per-protocol Set (PK-PPS) was a subset of the Safety Set, consisting of those study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Poor Metabolizers (PK-PPS)</title>
            <description>Poor metabolizers (Participants confirmed with genotype *2/*2, *2/*3, *3/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Metabolizers (PK-PPS)</title>
            <description>Intermediate metabolizers (Participants confirmed with genotype *1/*2,*1/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O3">
            <title>Extensive Metabolizers (PK-PPS)</title>
            <description>Extensive metabolizers (Participants confirmed with genotype *1/*1) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Padsevonil at Steady-state (ss)</title>
          <description>Cmax, ss is the maximum plasma concentration of PSL observed from pharmacokinetic samples, taken at predefined time point at a steady-state.</description>
          <population>The Pharmacokinetic Per-protocol Set (PK-PPS) was a subset of the Safety Set, consisting of those study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1375" lower_limit="1154" upper_limit="1639"/>
                    <measurement group_id="O2" value="1318" lower_limit="1106" upper_limit="1570"/>
                    <measurement group_id="O3" value="1263" lower_limit="1060" upper_limit="1505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Point estimates for the geometric least squares (LS) means ratio and the respective 2-sided 90% CIs were computed using the LS means and the root mean squares of error, based on of the log-transformed data with subsequent exponential transformation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS means ratio</param_type>
            <param_value>1.089</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8859</ci_lower_limit>
            <ci_upper_limit>1.339</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Point estimates for the geometric least squares (LS) means ratio and the respective 2-sided 90% CIs were computed using the LS means and the root mean squares of error, based on of the log-transformed data with subsequent exponential transformation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS means ratio</param_type>
            <param_value>1.044</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8489</ci_lower_limit>
            <ci_upper_limit>1.283</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Point estimates for the geometric least squares (LS) means ratio and the respective 2-sided 90% CIs were computed using the LS means and the root mean squares of error, based on of the log-transformed data with subsequent exponential transformation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS means ratio</param_type>
            <param_value>1.044</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8489</ci_lower_limit>
            <ci_upper_limit>1.283</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve Over a Dosing Interval (AUCtau) of Multiple Doses Padsevonil</title>
        <description>AUCtau is the area under the plasma concentration time curve over a dosing interval.</description>
        <time_frame>Day 10: Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after the morning dose</time_frame>
        <population>The Pharmacokinetic Per-protocol Set (PK-PPS) was a subset of the Safety Set, consisting of those study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Poor Metabolizers (PK-PPS)</title>
            <description>Poor metabolizers (Participants confirmed with genotype *2/*2, *2/*3, *3/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Metabolizers (PK-PPS)</title>
            <description>Intermediate metabolizers (Participants confirmed with genotype *1/*2,*1/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O3">
            <title>Extensive Metabolizers (PK-PPS)</title>
            <description>Extensive metabolizers (Participants confirmed with genotype *1/*1) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve Over a Dosing Interval (AUCtau) of Multiple Doses Padsevonil</title>
          <description>AUCtau is the area under the plasma concentration time curve over a dosing interval.</description>
          <population>The Pharmacokinetic Per-protocol Set (PK-PPS) was a subset of the Safety Set, consisting of those study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.</population>
          <units>h*ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6482" lower_limit="5435" upper_limit="7730"/>
                    <measurement group_id="O2" value="6488" lower_limit="5441" upper_limit="7737"/>
                    <measurement group_id="O3" value="4824" lower_limit="4045" upper_limit="5753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Point estimates for the geometric least squares (LS) means ratio and the respective 2-sided 90% CIs were computed using the LS means and the root mean squares of error, based on of the log-transformed data with subsequent exponential transformation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS means ratio</param_type>
            <param_value>1.344</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.092</ci_lower_limit>
            <ci_upper_limit>1.653</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Point estimates for the geometric least squares (LS) means ratio and the respective 2-sided 90% CIs were computed using the LS means and the root mean squares of error, based on of the log-transformed data with subsequent exponential transformation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS means ratio</param_type>
            <param_value>0.9991</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8120</ci_lower_limit>
            <ci_upper_limit>1.229</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Point estimates for the geometric least squares (LS) means ratio and the respective 2-sided 90% CIs were computed using the LS means and the root mean squares of error, based on of the log-transformed data with subsequent exponential transformation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS means ratio</param_type>
            <param_value>1.345</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.093</ci_lower_limit>
            <ci_upper_limit>1.655</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Half-life (t1/2) of Multiple Doses Padsevonil</title>
        <description>The t1/2 is the apparent terminal half-life.</description>
        <time_frame>Day 10: Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after the morning dose</time_frame>
        <population>The Pharmacokinetic Per-protocol Set (PK-PPS) was a subset of the Safety Set, consisting of those study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Extensive Metabolizers (PK-PPS)</title>
            <description>Extensive metabolizers (Participants confirmed with genotype *1/*1) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Metabolizers (PK-PPS)</title>
            <description>Intermediate metabolizers (Participants confirmed with genotype *1/*2,*1/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O3">
            <title>Poor Metabolizers (PK-PPS)</title>
            <description>Poor metabolizers (Participants confirmed with genotype *2/*2, *2/*3, *3/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (t1/2) of Multiple Doses Padsevonil</title>
          <description>The t1/2 is the apparent terminal half-life.</description>
          <population>The Pharmacokinetic Per-protocol Set (PK-PPS) was a subset of the Safety Set, consisting of those study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Half-life values could not be estimated for more than one third of the participants due to at least one of the reasons (data points &lt; 3, Lambda_z interval &lt; 2x half-life, or Adjusted R^2 &lt; 0.8).</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Half-life values could not be estimated for more than one third of the participants due to at least one of the reasons (data points &lt; 3, Lambda_z interval &lt; 2x half-life, or Adjusted R^2 &lt; 0.8).</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Half-life values could not be estimated for more than one third of the participants due to at least one of the reasons (data points &lt; 3, Lambda_z interval &lt; 2x half-life, or Adjusted R^2 &lt; 0.8).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Concentration (Tmax) for Padsevonil at Steady-state (ss)</title>
        <description>The tmax, ss is the time of observed maximum plasma concentration at a steady-state.</description>
        <time_frame>Day 10: Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after the morning dose</time_frame>
        <population>The Pharmacokinetic Per-protocol Set (PK-PPS) was a subset of the Safety Set, consisting of those study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Extensive Metabolizers (PK-PPS)</title>
            <description>Extensive metabolizers (Participants confirmed with genotype *1/*1) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Metabolizers (PK-PPS)</title>
            <description>Intermediate metabolizers (Participants confirmed with genotype *1/*2,*1/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O3">
            <title>Poor Metabolizers (PK-PPS)</title>
            <description>Poor metabolizers (Participants confirmed with genotype *2/*2, *2/*3, *3/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. During the Multiple-dose Period, participants received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally. Participants formed the Pharmacokinetic Per Protocol Set (PK-PPS).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Concentration (Tmax) for Padsevonil at Steady-state (ss)</title>
          <description>The tmax, ss is the time of observed maximum plasma concentration at a steady-state.</description>
          <population>The Pharmacokinetic Per-protocol Set (PK-PPS) was a subset of the Safety Set, consisting of those study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.500" lower_limit="0.500" upper_limit="4.00"/>
                    <measurement group_id="O2" value="2.000" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O3" value="1.500" lower_limit="0.500" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Treatment Emergent Adverse Events During the Study</title>
        <description>An Adverse Event (AE) is any untoward medical occurrence in a participant or trial participant that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.</description>
        <time_frame>From Baseline until the Safety Follow-up Visit (up to Day 21)</time_frame>
        <population>The Safety Set (SS) consisted of all study participants who had received at least 1 dose of padsevonil.</population>
        <group_list>
          <group group_id="O1">
            <title>Extensive Metabolizers Single Dose (SS)</title>
            <description>Extensive metabolizers (Participants confirmed with genotype *1/*1) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Metabolizers Single Dose (SS)</title>
            <description>Intermediate metabolizers (Participants confirmed with genotype *1/*2,*1/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O3">
            <title>Poor Metabolizers Single Dose (SS)</title>
            <description>Poor metabolizers (Participants confirmed with genotype *2/*2, *2/*3, *3/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O4">
            <title>Extensive Metabolizers Multiple Dose (SS)</title>
            <description>Extensive metabolizers (Participants confirmed with genotype *1/*1) received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally of Multiple-dose Period. Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O5">
            <title>Intermediate Metabolizers Multiple Dose (SS)</title>
            <description>Intermediate metabolizers (Participants confirmed with genotype *1/*2,*1/*3) received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally of Multiple-dose Period. Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O6">
            <title>Poor Metabolizers Multiple Dose (SS)</title>
            <description>Poor metabolizers (Participants confirmed with genotype *2/*2, *2/*3, *3/*3) received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally of Multiple-dose Period. Participants formed the Safety Set (SS).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment Emergent Adverse Events During the Study</title>
          <description>An Adverse Event (AE) is any untoward medical occurrence in a participant or trial participant that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.</description>
          <population>The Safety Set (SS) consisted of all study participants who had received at least 1 dose of padsevonil.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="100"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment emergent adverse events were collected from Baseline until the Safety Follow-up Visit (up to Day 21)</time_frame>
      <desc>One participant could experience multiple adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Extensive Metabolizers Single Dose (SS)</title>
          <description>Extensive metabolizers (Participants confirmed with genotype *1/*1) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. Participants formed the Safety Set (SS).</description>
        </group>
        <group group_id="E2">
          <title>Intermediate Metabolizers Single Dose (SS)</title>
          <description>Intermediate metabolizers (Participants confirmed with genotype *1/*2,*1/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. Participants formed the Safety Set (SS).</description>
        </group>
        <group group_id="E3">
          <title>Poor Metabolizers Single Dose (SS)</title>
          <description>Poor metabolizers (Participants confirmed with genotype *2/*2, *2/*3, *3/*3) received a single oral dose of PSL 200 mg in the morning on Day 1 of the Single-dose Period. Participants formed the Safety Set (SS).</description>
        </group>
        <group group_id="E4">
          <title>Extensive Metabolizers Multiple Dose (SS)</title>
          <description>Extensive metabolizers (Participants confirmed with genotype *1/*1) received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally of Multiple-dose Period. Participants formed the Safety Set (SS).</description>
        </group>
        <group group_id="E5">
          <title>Intermediate Metabolizers Multiple Dose (SS)</title>
          <description>Intermediate metabolizers (Participants confirmed with genotype *1/*2,*1/*3) received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally of Multiple-dose Period. Participants formed the Safety Set (SS).</description>
        </group>
        <group group_id="E6">
          <title>Poor Metabolizers Multiple Dose (SS)</title>
          <description>Poor metabolizers (Participants confirmed with genotype *2/*2, *2/*3, *3/*3) received PSL 100 mg BID on Day 6, PSL 200 mg BID from Day 7 to Day 9, PSL 200 mg in the morning on Day 10; PSL 100 mg in the evening on Day 10, and PSL 100 mg BID from Day 11 to Day 12 orally of Multiple-dose Period. Participants formed the Safety Set (SS).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA22.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E4" events="73" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E5" events="78" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E6" events="84" subjects_affected="13" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="13"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E4" events="23" subjects_affected="7" subjects_at_risk="13"/>
                <counts group_id="E5" events="28" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E6" events="29" subjects_affected="8" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" events="7" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB</name_or_title>
      <organization>Cares</organization>
      <phone>+1844599 ext 2273</phone>
      <email>UCBCares@ucb.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

